Literature DB >> 11817972

A new role for opioids in the treatment of arthritis.

Sanford H Roth1.   

Abstract

Arthritis, rheumatic diseases, spinal and peripheral joint disorders share in common a legacy of chronic pain. At the turn of the millennium, nonsteroidal anti-inflammatories (NSAIDs) had replaced aspirin as the agents most commonly used to deal with rheumatic symptoms, including pain. Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain. Opioids were most commonly used on an ad-lib basis, usually for 'breakthrough' pain. However, neurobiological research has confirmed the basis for 24-hour around-the-clock complete suppression of chronic nonmalignant pain. This avoids the 'wind up' that leads to intractable pain progression. Proper monitoring, in the absence of the end organ toxicity seen with NSAIDs, allows a change in direction to opioids for arthritis for more severe pain. This requires understanding the responsibilities of maintaining opioids, in properly selected patients, based upon host response and informed consent. Under such circumstances, evidence-based trials support the use of stronger opioids in recalcitrant chronic pain of arthritis. Thus, we endeavour to better fulfill our Oath of Hippocrates: 'to relieve pain and suffering'.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11817972     DOI: 10.2165/00003495-200262020-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  52 in total

Review 1.  NSAID gastropathy. A new understanding.

Authors:  S H Roth
Journal:  Arch Intern Med       Date:  1996 Aug 12-26

Review 2.  Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response.

Authors:  S H Roth; R E Bennett
Journal:  Arch Intern Med       Date:  1987-12

Review 3.  Selection of analgesic therapies in rheumatoid arthritis: the role of opioid medications.

Authors:  G R Gonzales; R K Portenoy
Journal:  Arthritis Care Res       Date:  1993-12

4.  The experience of chronic nonmalignant pain.

Authors:  L S Hitchcock; B R Ferrell; M McCaffery
Journal:  J Pain Symptom Manage       Date:  1994-07       Impact factor: 3.612

5.  Addiction rare in patients treated with narcotics.

Authors:  J Porter; H Jick
Journal:  N Engl J Med       Date:  1980-01-10       Impact factor: 91.245

6.  Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis.

Authors:  G J Vlok; J P van Vuren
Journal:  S Afr Med J       Date:  1987-10-17

7.  Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.

Authors:  M E Hale; R Fleischmann; R Salzman; J Wild; T Iwan; R E Swanton; R F Kaiko; P G Lacouture
Journal:  Clin J Pain       Date:  1999-09       Impact factor: 3.442

Review 8.  Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states.

Authors:  C R Lee; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

9.  Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.

Authors:  J F Fries; C A Williams; D A Bloch; B A Michel
Journal:  Am J Med       Date:  1991-09       Impact factor: 4.965

10.  Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.

Authors:  G Singh; D R Ramey; D Morfeld; H Shi; H T Hatoum; J F Fries
Journal:  Arch Intern Med       Date:  1996-07-22
View more
  5 in total

1.  What is the role of NSAIDs in pre-emptive analgesia?

Authors:  Sandford H Roth
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Understanding the COX-2/NSAID dilemma.

Authors:  Sanford H Roth
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  [Physicians' knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain].

Authors:  M Pflughaupt; R Scharnagel; G Gossrau; U Kaiser; T Koch; R Sabatowski
Journal:  Schmerz       Date:  2010-06       Impact factor: 1.107

4.  Modulating β-arrestin 2 recruitment at the δ- and μ-opioid receptors using peptidomimetic ligands.

Authors:  Krishna K Sharma; Robert J Cassell; Yazan J Meqbil; Hongyu Su; Arryn T Blaine; Benjamin R Cummins; Kendall L Mores; David K Johnson; Richard M van Rijn; Ryan A Altman
Journal:  RSC Med Chem       Date:  2021-08-16

Review 5.  Transdermal buprenorphine.

Authors:  Hannah C Evans; Stephanie E Easthope
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.